Via Pharmaceuticals cardiovascular, metabolic, endocrine news

Via restructured and reduced headcount by 10 (63%) to six, reducing its workforce to a core R&D team. The cuts include SVP and CFO James Stewart. Via's lead compound is VIA-2291, an oral reversible 5-lipoxygenase ( ALOX5; 5-LO) inhibitor in Phase II testing for secondary prevention of major adverse cardiovascular events in acute coronary syndrome (ACS) patients. Data are expected this half. ...